



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/646,852	09/22/2000	Per Johan Lundberg	1103326-0636	1116
7470	7590	09/04/2008	EXAMINER	
WHITE & CASE LLP PATENT DEPARTMENT 1155 AVENUE OF THE AMERICAS NEW YORK, NY 10036			TRAN, SUSAN T	
ART UNIT	PAPER NUMBER	1618		
MAIL DATE	DELIVERY MODE	09/04/2008 PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	09/646,852	LUNDBERG ET AL.
	Examiner S. Tran	Art Unit 1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(o).

Status

1) Responsive to communication(s) filed on 12 June 2008.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1,3-10,12-18,20 and 23-31 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1,3-10,12-18,20 and 23-31 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SE/CC)
Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date _____

5) Notice of Informal Patent Application

6) Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 06/12/08 has been entered.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 3-10, 12-18, 20 and 23-31 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. It appears that the specification does not provide support for the limitation that the semipermeable membrane is "the outer most layer of the dosage form". This is because the present specification discloses that the active core coated with the claimed semipermeable

membrane is than filled into capsule or compressed into tablet. The tablet is further coated with a film forming layer (page 9, first paragraph).

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 3-10, 12-18, 20 and 23-31 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims are rejected in the use of the limitation that requires the semipermeable membrane be the "outermost layer of the dosage form" as recited in claim 1. It is not entirely clear what this limitation is referring to, because the present specification clearly discloses that the dosage form is further coated with a film forming agent, or encapsulated in a gelatin or HPMC capsule (see page 9, first paragraph). In view of this and the "comprising language" in the preamble of the claim, for examining purpose, the claims are interpreted to permit other coatings.

Claim Rejections - 35 USC § 103

Claims 1, 3, 6-8, 12-18, 20 and 25-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nara et al. US 6,245,351, in view of Bergstrand et al. US 5,753,265.

Nara teaches a controlled release composition comprising a drug-containing core coated with a protective coating layer containing hydrophilic substances (column 6, lines

1-10). Hydrophilic substances include hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methylcellulose, polyvinylpyrrolidone, and polyvinyl alcohol (column 5, lines 1-4). The amount of this protective coating is about 1 to about 15% to the core (ID). Drugs include omeprazole and lansoprazole (column 3, lines 59-60). The drug is mixed with excipient, such as sucrose or calcium phosphate (osmotic agent); binder; disintegrant, such as, sodium crosslinked carboxymethylcellulose or low-substitutional hydroxypropyl cellulose (swelling agent); and lubricant, including talc (alkaline additive) (column 5, lines 36-52; and examples). The core can be in the form of a granule, fine granule, or inert carrier particles including sucrose (column 5, lines 30-35, and 60-65). The coated core can be prepared in tablet or capsule form for oral administration (column 6, lines 56-65; and claim 7).

Nara does not explicitly teach the addition of a modifying agent in the protective coating composition.

Bergstrand teaches an omeprazole core is coated with a separating layer (protective coating layer) comprising polymer such as ethylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, methylcellulose, and polyvinyl alcohol (column 7, lines 51-61). Bergstrand further teaches the polymer can be used alone (as a single polymer) (column 7, line 62). The separating layer further comprises plasticizer, and antistatic agents such as talc (column 7, lines 63-65; and examples 1, 3 and 7). Thus, it would have been obvious to one of ordinary skill in the art to modify the protective coating composition of Nara to include additives such as talc in view of the teaching of Bergstrand to obtain the claimed invention, because Bergstrand teaches adding talc to

the coating composition to increase the thickness of the layer and thereby strengthen the diffusion barrier, because Bergstrand teaches the separating layer improves the chemical stability of the active substance and the physical properties of the dosage form (column 8, lines 21-27), because Nara teaches the desirability of using a separating layer to protect the acid sensitive active core, and because Nara teaches the use of other agent to help modify the coating properties (modifying agent) (example 11, lines 49-50).

Regarding the limitation "water-insoluble polymer capable of forming a semipermeable membrane", it is noted that Nara and Bergstrand teach the use of the claimed water-insoluble polymers. Therefore, the burden is shifted to applicant to show that the water-insoluble polymers taught by Nara and Bergstrand do not have the claimed property. This is because identical chemical composition cannot have mutually exclusive properties. A chemical composition and its properties are inseparable. *In re Spada*, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990).

Claims 30 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nara et al. US 6,245,351, in view of Bergstrand et al. US 5,753,265 and Hodges et al. US 5,225,202.

Nara is relied upon for the reason stated above. Nara does not explicitly teach the amount of alkaline additive present in the core.

Hodges teaches a controlled release pellet comprising acid labile drug in the core, and one or more buffering agents (alkaline additives) (see abstract, and column 3,

lines 1-4; lines 15-19). Buffering agents present in the core in an amount ranging from about 1 to about 20% (column 3, lines 34-36). Thus, it would have been obvious to one of ordinary skill in the art to use alkaline additive in an amount taught by Hodges to obtain a stable acid labile composition, because Hodges teaches using buffering agent in an amount of about 1 to about 20% to aid in minimizing drug degradation in the core due to acid ingress in low pH environments (column 3, lines 6-9), and because Nara teaches a composition with low toxicity and can be safely used in mammals.

It is noted that Nara does not explicitly teach the weight ratio of the modifying agent to water-insoluble substance, as well as the amount of the alkaline additive and swelling agent in the core. However, generally, differences in concentration will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration is critical. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Thus, it would have been obvious to one of ordinary skill in the art to, by routine experimentation determine suitable amount of talc in the core composition as well as in the coating composition, because Nara teaches the release rate of the active ingredient is mainly in the small and large intestine without an enteric coating, while the release rate of the active ingredient is very limited in the stomach (column 1, lines 53-55; and column 7, lines 25-31), and because Nara teaches a coated formulation with low toxicity that can be safely used in human. The expected result would be a controlled-release composition comprising omeprazole in the core without

enteric coating that can limit release of omeprazole in the stomach, but increases release in the small and large intestine.

Claims 9 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nara et al. US 6,245,351, in view of Bergstrand et al. and, Zentner US 4,795,644 or Lundberg et al. 6,013,281.

Nara is relied upon for the reasons stated above. Nara is silent of the claimed alkaline agent.

Zentner teaches pH-modifying agent includes sodium mono- or di-phosphate (column 8, lines 3-15).

Lundberg teaches alkaline reacting compound includes arginine (column 6, lines 50-55). Thus, it would have been obvious to one of ordinary skill in the art to modify the compositions of Nara using sodium mono- or di-phosphate and arginine compound as an alkaline agent, because the references teach suitable composition for the same active agent, namely, omeprazole, and because Nara teaches the desirability of using an alkaline agent in the composition.

Claims 4, 5 and 23-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nara et al. US 6,245,351, in view of Bergstrand et al., and Cotton et al. WO 98/54171.

Nara is relied upon for the reasons stated above. Nara is deficient in the fact that Nara does not specifically teach magnesium salt of omeprazole.

Cotton teaches novel form of S-enantiomer of omeprazole, including S-omeprazole, and more specifically, magnesium salt of S-omeprazole trihydrate (hereafter, the compound) (see abstract, and page 1, lines 4-10). Cotton also teaches the compound is formulated into oral dosage form, e.g., capsule, tablet, and the like (page 6, lines 15-30). The formulation is effective as a gastric acid secretion inhibitor and is useful as an anti-ulcer agent (page 6, lines 1-14).

Cotton does not explicitly teach the compound having a crystallinity of more than 70%, however, Cotton teaches that the compound of his invention is highly crystalline, i.e., having a higher crystallinity than any other form of magnesium salt of S-omeprazole in the prior art (page 3, lines 24 through page 4, lines 1-7). Therefore, the burden is shifted to applicant to show the compound taught by Cotton does not have the crystallinity being claimed. It is also noted that Cotton teaches the trihydrate form, e.g., magnesium salt of S-omeprazole "trihydrate". However, applicant claims recite a generic form of magnesium salt of S-omeprazole with the transitional phrase "comprising of" permits any other form, including "trihydrate" taught by Cotton. Thus, it would have been obvious for one of ordinary skill in the art to modify the controlled release composition comprising a drug-containing core coated with a *non-enteric* coating composition using the magnesium salt of S-omeprazole trihydrate in view of the teaching of Cotton, because Cotton teaches the compound of his invention is more stable, easier to handle and store, easier to synthesize in a reproducible manner, because Cotton teaches the compound is most preferred in oral administration formulation, because Nara teaches a non-enteric coated formulation with low toxicity

that can be safely used in human. The expected result would be a controlled-release composition comprising omeprazole in the core without enteric coating that can limit release of omeprazole in the stomach, but increases release in the small and large intestine.

Response to Arguments

Applicant's arguments filed 06/21/08 have been fully considered but they are not persuasive.

Applicant argues that gelatin capsule is not the structural or functional equivalent of an outermost layer of a semipermeable membrane coring the core material. Firstly, a gelatin capsule is not able to disrupt but dissolve in the stomach to release its contents. Secondly, the claimed invention requires that a sufficient amount of the semipermeable membrane composition layer and cover the core material. A gelatin capsule encloses and contains its multiple unit contents, e.g., pellets, but does not layer and cover each multiple unit as required by the claimed invention.

However, in response to applicant's argument, the burden is shifted to applicant to show that the HPMC capsule and the film forming polymer of the tablet coating layer, are not able to disrupt. The capability of being disrupt is inherent since Nara teaches the use of a similar polymer, namely, a cellulosic polymer. Further, applicant's attention is called to the disclosure in the present specification at page 3, lines 15-24 for the teachings that the present of one or more swelling agents in the core to effectuate a disruption. Accordingly, the disruption of the coating layer is further facilitated by the

present of the swelling agents in the core, not the coating polymer itself. Moreover, in response to applicant's argument that Nara fails to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., the claimed invention requires that a sufficient amount of the semipermeable membrane composition layer and cover the core material) are not recited in the rejected claims. The claims do not require any sufficient amount of coating. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Applicant argues that in contrast to the claimed invention, Nara discloses a coating composition comprised of two or three polymers: a water insoluble polymer; a swellable polymer; and an optional hydrophilic substance (See claims 1 and 9). Such a two- or three-polymer system does not suggest the single polymer coating composition of the claimed invention. In summary, Nara discloses a coating composition comprising at least two polymers: a water insoluble polymer and a swellable polymer. Thus, it can be said that Nara teaches away from the claimed invention which is characterized by a semipermeable membrane comprising a single polymer composition containing a water insoluble polymer.

However, in response to applicant's arguments, it is noted that the comprising language in the preamble of the claims does not preclude the separating/protective coating layer taught by Nara. This protective coating layer comprises a single polymer, such as ethyl cellulose (column 6, lines 4-10; and example 11). Accordingly, Nara

meets the requirement for the limitation coating comprises a single polymer. Further, Nara is cited in combination with Bergstrand for the teaching of adding modifying agent to an intermediate coating layer is well known in the art, much less to an intermediate coating layer of the same drug, e.g., omeprazole. It is noted that one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

Applicant argues that the combination of Nara and Bergstrand fails to suggest the claimed invention since the coating composition disclosed by the primary reference to Nara is characterized by a mixture of two or three polymers: a water insoluble polymer; a swellable polymer; and an optional hydrophilic substance. In contrast, the claimed dosage form is distinguishable over the cited combination of references by a semipermeable membrane comprising a single polymer composition containing a water insoluble polymer and wherein the dosage form is not enteric coated.

However, as discussed above, the Nara reference clearly teaches a coating layer that comprises a single polymer such as ethyl cellulose. Thus, the combination of Nara and Bergstrand suggests the claimed invention.

Applicant argues that the combinations of Nara and Bergstrand and Hodges, or Nara and Bergstrand and Zentner or Lundberg, or Nara and Bergstrand and Cotton fail to suggest the claimed invention since the coating composition disclosed by the

primary reference to Nara is characterized by a mixture of two or three polymers: a water insoluble polymer; a swellable polymer; and an optional hydrophilic substance.

However, as stated above, the Nara reference clearly teaches a coating layer that comprises a single polymer such as ethyl cellulose. Accordingly, the teaching of Nara meets the claimed limitations.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to S. Tran whose telephone number is (571) 272-0606. The examiner can normally be reached on M-F 8:00 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/S. Tran/
Primary Examiner, Art Unit 1618